Back to Search
SAIF-ELDIN FARAG, DO
DO
Internal Medicine Physician
NPI: 1689314585IndividualAccepts Medicare
Education
OTHER
Class of 2022
Research & Publications (20)
New isoflavone glycosides from Iris spuria L. (Calizona) cultivated in Egypt.
PMID 18791667·J Nat Med·2009
8-other
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.
PMID 19261329·Leuk Res·2009
3-trial
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
PMID 18082257·Leuk Res·2008
3-trial
Antimyeloma effects of a sesquiterpene lactone parthenolide.
PMID 18347184·Clin Cancer Res·2008
8-other
Fructose-amino acid conjugate and other constituents from Cyperus rotundus L.
PMID 19023813·Nat Prod Res·2008
8-other
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
PMID 18541197·Biol Blood Marrow Transplant·2008
3-trial
Musculoskeletal affections among kidney recipients: prevalence and risk predictors.
PMID 18443795·Rheumatol Int·2008
8-other
Multiple myeloma. Clinical practice guidelines in oncology.
PMID 17335683·J Natl Compr Canc Netw·2007
6-review
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.
PMID 17317850·Blood·2007
8-other
OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
PMID 17699852·Clin Cancer Res·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 202 S PARK ST, MERITER HOSPITAL
MADISON, WI 53715 - Phone
- (608) 417-5695
Quick Facts
- NPI
- 1689314585
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile